Trial Profile
Clinical Trial evaluating the correlation of clinical efficacy of alternative antiandrogens and UFT therapy with mRNA expression of enzymes related to 5-FU metabolism in patients with prostate cancer who relapsed after maximum androgen blockade
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2019
Price :
$35
*
At a glance
- Drugs Tegafur/uracil (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Oct 2017 New trial record